Glöckner, A., Schönland, S., Einsele, H., & Kröger, N. (2025). Rationale and design of the multicenter, national, randomized, open labeled phase III trial: Allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study). BMC cancer, 25, . https://doi.org/10.1186/s12885-025-13503-7
Chicago-Zitierstil (17. Ausg.)Glöckner, Annemarie, Stefan Schönland, Hermann Einsele, und Nicolaus Kröger. "Rationale and Design of the Multicenter, National, Randomized, Open Labeled Phase III Trial: Allogeneic Stem Cell Transplantation as a Potential Curative Treatment for Patients with Relapsed or Progressed Multiple Myeloma (AlloRelapseMM Study)." BMC Cancer 25 (2025). https://doi.org/10.1186/s12885-025-13503-7.
MLA-Zitierstil (9. Ausg.)Glöckner, Annemarie, et al. "Rationale and Design of the Multicenter, National, Randomized, Open Labeled Phase III Trial: Allogeneic Stem Cell Transplantation as a Potential Curative Treatment for Patients with Relapsed or Progressed Multiple Myeloma (AlloRelapseMM Study)." BMC Cancer, vol. 25, 2025, https://doi.org/10.1186/s12885-025-13503-7.